MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Alimera Sciences Company Profile (NASDAQ:ALIM)

Consensus Ratings for Alimera Sciences (NASDAQ:ALIM) (?)
Ratings Breakdown: 1 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $4.50 (221.43% upside)

Analysts' Ratings History for Alimera Sciences (NASDAQ:ALIM)
Show:
DateFirmActionRatingPrice TargetActions
5/5/2016Cowen and CompanyDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2016Cantor FitzgeraldLower Price TargetBuy$6.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/26/2015Credit SuisseLower Price Target$5.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/17/2014Summer StreetInitiated CoverageBuy -> Buy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/29/2014Northland SecuritiesBoost Price TargetOutperform$7.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Alimera Sciences (NASDAQ:ALIM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/4/2016Q1($0.19)($0.22)$5.83 million$5.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.21)($0.21)$6.96 million$6.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.22)($0.25)$6.49 million$5.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.24)($0.27)$3.90 million$3.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2015Q414$0.17($0.28)$5.11 million$1.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($0.70)($0.22)$3.75 million$2.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.23)($0.15)$2.70 million$2.19 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.25)($0.20)$1.15 million$2.08 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413($0.29)($0.24)$0.75 million$0.94 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2013Q313($0.30)($0.26)$0.38 million$0.76 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2013Q2 2013($0.24)($0.30)$3.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.26)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/21/2013Q4 2012($0.23)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.19)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/8/2012($0.24)($0.19)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2011($0.19)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2011($0.18)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2011($0.20)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2011($0.22)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Alimera Sciences (NASDAQ:ALIM)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Alimera Sciences (NASDAQ:ALIM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Alimera Sciences (NASDAQ:ALIM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/21/2016L.P. BavpMajor ShareholderSell478,673$2.59$1,239,763.07View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2015Richard S. Eiswirth, Jr.CFOSell46,669$2.31$107,805.39View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2015James E FlynnInsiderBuy272,249$3.01$819,469.49View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015James E FlynnInsiderBuy243,252$3.00$729,756.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2015James E FlynnInsiderBuy16,542$3.00$49,626.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/28/2015James E FlynnInsiderBuy59,342$3.00$178,026.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015James E FlynnInsiderBuy60,364$3.00$181,092.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2015James E FlynnMajor ShareholderBuy160,684$3.00$482,052.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/20/2015James E FlynnMajor ShareholderBuy100,130$3.00$300,390.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/19/2015James E FlynnMajor ShareholderBuy129,226$2.92$377,339.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Richard S. Eiswirth, Jr.CFOSell13,625$2.69$36,651.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/9/2015James E FlynnInsiderBuy321,785$2.42$778,719.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2015Calvin W RobertsDirectorBuy6,424$3.00$19,272.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2015Kenneth GreenSVPSell20,000$3.29$65,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Kenneth GreenSVPSell20,000$3.90$78,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2015L.P. BavpMajor ShareholderSell1,024$5.00$5,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015L.P. BavpMajor ShareholderSell5,568$5.00$27,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2015C. Daniel MyersCEOSell2,000$4.37$8,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/27/2015L.P. BavpMajor ShareholderSell3,114$5.02$15,632.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/23/2015L.P. BavpMajor ShareholderSell4,362$5.00$21,810.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2015L.P. BavpMajor ShareholderSell30,300$5.03$152,409.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015L.P. BavpMajor ShareholderSell35,800$5.03$180,074.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2015L.P. BavpMajor ShareholderSell18,400$5.01$92,184.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/13/2015L.P. BavpMajor ShareholderSell100$5.00$500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2015Richard S Eiswirth JrCFOBuy10,000$4.84$48,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015C. Daniel MyersCEOSell2,000$5.21$10,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015C. Daniel MyersCEOSell2,000$5.51$11,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015David HollandSVPSell5,000$5.56$27,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014C. Daniel MyersCEOSell2,000$5.99$11,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014David HollandSVPSell5,000$5.71$28,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2014L.P. BavpMajor ShareholderSell57,918$6.34$367,200.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014C. Daniel MyersCEOSell2,000$5.42$10,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014David HollandSVPSell5,000$5.26$26,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Patrick LeeMajor ShareholderSell621,191$5.42$3,366,855.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2014Patrick LeeMajor ShareholderSell354,062$5.42$1,919,016.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014Patrick LeeMajor ShareholderSell240,662$5.47$1,316,421.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2014L.P. BavpMajor ShareholderSell2,816$6.25$17,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2014L.P. BavpMajor ShareholderSell39,500$6.33$250,035.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2014L.P. BavpMajor ShareholderSell7,400$6.27$46,398.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2014L.P. BavpMajor ShareholderSell3,000$6.27$18,810.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014David HollandSVPSell5,000$5.64$28,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014David HollandSVPSell5,000$6.02$30,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014David HollandSVPSell5,000$5.93$29,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2014C. Daniel MyersCEOSell22,775$7.10$161,702.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2014David HollandSVPSell10,000$6.84$68,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2014Susan CaballaInsiderSell8,931$7.01$62,606.31View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2014Domain Partners Vi, L.P.Major ShareholderSell296,760$6.39$1,896,296.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2013Polaris Venture Management CoInsiderSell122,937$4.80$590,097.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2013Domain Partners Vi, L.P.Major ShareholderSell10,516$5.01$52,685.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2013Domain Partners Vi, L.P.Major ShareholderSell55,278$5.39$297,948.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2013Polaris Venture Management CoInsiderSell37,063$5.44$201,622.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2013Domain Partners Vi, L.P.Major ShareholderSell126,709$5.29$670,290.61View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2013Domain Partners Vi, L.P.Major ShareholderSell5,337$5.00$26,685.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2013David HollandSVPSell30,000$4.13$123,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2013Domain Partners Vi, L.P.Major ShareholderSell44,242$4.60$203,513.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/13/2012Peter J Pizzo IIIDirectorBuy5,000$1.44$7,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2012C. Daniel MyersCEOSell7,700$1.95$15,015.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Alimera Sciences (NASDAQ:ALIM)
DateHeadline
06/24/16 02:25 PMShares Dropping to a Recent Low: Alimera Sciences, Inc. (NASDAQ:ALIM) - Press Telegraph
06/23/16 03:52 PMAlimera Sciences Inc. (ALIM) Drops 6.17% on June 21 - Equities.com
06/14/16 07:12 AMAlimera Sciences Inc. (ALIM) Jumps 5.81% on June 13 - Equities.com
06/10/16 10:52 AMDiabetic Retinopathy Treatment Industry to Reach $10.24 billion by 2022
06/07/16 07:59 PMAlimera Sciences Inc. (ALIM) Jumps 5.56% on June 06 - Equities.com
06/02/16 11:03 AMAlimera Sciences Inc. (ALIM) is Trading Lower on Unusual Volume for May 31 - Equities.com - Alimera Sciences Inc. (ALIM) is Trading Lower on Unusual Volume for May 31Equities.comAlimera Sciences Inc. (ALIM) experienced unusually high volume on May. 31, as the stock lost 0.65% to a closing price of $1.54. The stock saw 718,584 shares trade hands over the course of the day on 1,629 trades. Given that the stock's average daily ...
06/02/16 06:05 AMAlimera Sciences to Present at the LD Micro Invitational Conference - [at noodls] - June 2, 2016 ATLANTA, June 02, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences (NASDAQ:ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced ...
05/30/16 01:49 PMPerformance at a Glance on Alimera Sciences, Inc. (NASDAQ:ALIM) - HNN - Performance at a Glance on Alimera Sciences, Inc. (NASDAQ:ALIM)HNNWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how Alimera Sciences, Inc. (NASDAQ:ALIM)'s stock has performed at various points in its past. Currently ...and more »
05/27/16 03:06 PMALIMERA SCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit -
05/26/16 12:01 PMAlimera Sciences Inc. (ALIM) is Trading Higher on Unusual Volume for May 24 - Equities.com - Alimera Sciences Inc. (ALIM) is Trading Higher on Unusual Volume for May 24Equities.comAlimera Sciences Inc. (ALIM) experienced unusually high volume on May. 24, as the stock gained 4.7% to a closing price of $1.56. The stock saw 1.53 million shares trade hands over the course of the day on 1,805 trades. Given that the stock's average ...
05/25/16 12:06 PMStocks Growth Update: Alimera Sciences Inc (ALIM), Sociedad Quimica y Minera de Chile (SQM) - News Oracle - Stocks Growth Update: Alimera Sciences Inc (ALIM), Sociedad Quimica y Minera de Chile (SQM)News OracleThe stock gained 4.70% and closed its last session at $1.56. The Company has the market capitalization of 68.96 Million. The 52-Week Range ranges between $1.43 and $5.15. The stock traded with the Volume of 1.53 Million in the last trading day whereas, ...and more »
05/25/16 12:06 PMStocks In The News: Alimera Sciences Inc (NASDAQ:ALIM), Boston Scientific Corporation (NYSE:BSX) - NYSE Journal (press release) - Stocks In The News: Alimera Sciences Inc (NASDAQ:ALIM), Boston Scientific Corporation (NYSE:BSX)NYSE Journal (press release)On Tuesday, Shares of Alimera Sciences Inc (NASDAQ:ALIM), added 4.70% and closed at $1.56 in the last trading session. The last trading range of the stock ranges between $1.48 and $1.69. Alimera Sciences Limited, the European partner of Alimera ...Drug Stocks to Watch: Alimera Sciences, (NASDAQ:ALIM), Immune Pharmaceuticals, Inc. (NASDAQ:IMNP), Skystar Bio ...KC Registerall 4 news articles »
05/23/16 03:06 PMReal World Data In Europe Show Majority Of Diabetic Macular Edema Patients Gain Or Maintain Vision With Iluvien® At 12 Months - [at noodls] - May 23, 2016 Despite other prior treatments, improvements in visual acuity and retinal thickness were seen in the majority of patients Efficacy and safety data are comparable with Phase III FAME clinical ...
05/22/16 01:28 PMAlimera Sciences Inc. (ALIM) Hits New 52-week Low During May 19 Session - Equities.com - Alimera Sciences Inc. (ALIM) Hits New 52-week Low During May 19 SessionEquities.comAlimera Sciences Inc. (ALIM) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $1.51, Alimera Sciences Inc. dropped to $1.43 for a new 52-week low. By the closing bell, the company's stock was at ...
05/19/16 05:55 PMETF’s with exposure to Alimera Sciences, Inc. : May 19, 2016 -
05/19/16 11:58 AMCowen & Company Downgrades Alimera Sciences Inc to Market Perform - Trade Calls - Cowen & Company Downgrades Alimera Sciences Inc to Market PerformTrade CallsBrokerage firm Cowen & Company Downgrades its rating on Alimera Sciences Inc(NASDAQ:ALIM). The shares have been rated Market Perform. Previously, the analysts had a Outperform rating on the shares. The rating by Cowen & Company was issued on ...Recently Changed Price Targets On Alimera Sciences, Inc. (ALIM)Risers & FallersAlimera Sciences Incorporated (NASDAQ:ALIM) Shorted Shares Increased 6.38% After Market SellingWall Street Hints and Newsall 4 news articles »
05/18/16 12:42 PMRevenue Update on Alimera Sciences Inc(NASDAQ:ALIM) - Trade Calls - Revenue Update on Alimera Sciences Inc(NASDAQ:ALIM)Trade CallsAlimera Sciences Inc(NASDAQ:ALIM) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 4, 2016. Company reported revenue of $5.80M. Analysts estimated a revenue of $6.16M. Earnings per share ...Latest Analyst Ratings For Alimera Sciences, Inc. (ALIM)Share Trading NewsAlimera Sciences Incorporated (NASDAQ:ALIM) Shorted Shares Increased 6.38% After Market SellingWall Street Hints and Newsall 3 news articles »
05/18/16 12:16 PMAlimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/17/16 12:04 PMALIMERA SCIENCES INC Financials -
05/17/16 07:42 AMAlimera Sciences to Present at the UBS Global Healthcare Conference - [at noodls] - May 17, 2016 ATLANTA, May 17, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences (NASDAQ:ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced ...
05/12/16 06:41 AMAlimera Sciences (ALIM) Presents Post-Marketing Study Data on ILUVIEN at SFO 2016 - StreetInsider.com - Alimera Sciences (ALIM) Presents Post-Marketing Study Data on ILUVIEN at SFO 2016StreetInsider.comAlimera Sciences, Inc. (Nasdaq: ALIM) announced that data from six ILUVIEN® post marketing studies were presented during the French Society of Ophthalmology 122nd Congress (SFO 2016) in Paris May 7-10. The six Alimera data presentations at SFO ...and more »
05/11/16 06:30 AMAlimera Sciences' ILUVIEN® Data Presented at SFO 2016 - [GlobeNewswire] - ATLANTA, May 11, 2016-- Alimera Sciences, Inc., a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that data from six ILUVIEN ® post marketing ...
05/11/16 05:58 AMAlimera Sciences Inc. (ALIM) Drops 7.26% on May 09 - Equities.com - Alimera Sciences Inc. (ALIM) Drops 7.26% on May 09Equities.comAlimera Sciences Inc. (ALIM) was one of the Russell 2000's biggest losers for Monday May 09 as the stock slid 7.26% to $1.73, a loss of $-0.135 per share. Starting at an opening price of $1.88 a share, the stock traded between $1.67 and $1.88 over the ...and more »
05/09/16 06:15 AMAlimera Sciences, Inc. (ALIM) Broker Price Targets For The Coming Week - Share Trading News - Alimera Sciences, Inc. (ALIM) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Alimera Sciences, Inc. (ALIM). The latest reports which are currently in issue on Sunday 8th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...and more »
05/06/16 03:22 PMEdited Transcript of ALIM earnings conference call or presentation 5-May-16 2:00pm GMT -
05/06/16 03:11 PMALIMERA SCIENCES INC Files SEC form 10-Q, Quarterly Report -
05/06/16 06:44 AMAlimera Sciences' ILUVIEN® Data Presented At 2016 ARVO - [at noodls] - ATLANTA, May 6, 2016 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced ...
05/06/16 06:27 AMAlimera Sciences Inc. (ALIM) Drops 13.12% on May 05 - Equities.com - Web Breaking NewsAlimera Sciences Inc. (ALIM) Drops 13.12% on May 05Equities.comAlimera Sciences Inc. (ALIM) was one of the Russell 2000's biggest losers for Thursday May 05 as the stock slid 13.12% to $1.92, a loss of $-0.29 per share. Starting at an opening price of $2.10 a share, the stock traded between $1.76 and $2.13 over ...Alimera Sciences Slides 14% After Missing Q1 Estimates (NASDAQ:ALIM)Sonoran Weekly ReviewAlimera Sciences Inc (ALIM) Trading Down 9% Following Weak EarningsWeb Breaking NewsAlimera Sciences' (ALIM) CEO Dan Myers on Q1 2016 Results - Earnings Call TranscriptSeeking Alphaall 7 news articles »
05/04/16 06:48 PMAlimera Sciences reports 1Q loss -
05/04/16 03:51 PMAlimera Sciences Announces First Quarter 2016 Financial Results - [at noodls] - May 4, 2016 First quarter revenue improved 49% compared to first quarter 2015 due to increasing ILUVIEN® sales in the U.S. ... This is an abstract of the original noodl. To continue reading this document, ...
05/04/16 06:07 AMQ1 2016 Alimera Sciences Inc Earnings Release - After Market Close -
05/04/16 05:24 AMDiabetic Retinopathy Treatment Industry to Grow at a CAGR of 18.6% to 2022 - According to Researcher, the Global Diabetic Retinopathy Treatment market is expected to reach $10.24 billion by 2022. Rising prevalence of diabetics, increasing management financial support, change in lifestyle and global aging population are the factors ...
05/04/16 05:24 AMGlobal Diabetic Retinopathy Treatment Market 2016 Analysis and Forecasts to 2022 - WiseGuyReports.com adds “Diabetic Retinopathy Treatment - Global Market Outlook (2015-2022)” new report to its research database. PUNE, INDIA, May 2, 2016 /EINPresswire.com/ -- According to Researcher, the Global Diabetic Retinopathy Treatment market ...
05/02/16 06:06 AMBroker Roundup For Alimera Sciences, Inc. (ALIM) - Share Trading News - Broker Roundup For Alimera Sciences, Inc. (ALIM)Share Trading News09/29/2014 – Alimera Sciences, Inc. had its “outperform” rating reiterated by analysts at Northland Securities. They now have a USD 10 price target on the stock. The share price of Alimera Sciences, Inc. (ALIM) was down -5.93% during the last trading ...
04/29/16 06:41 AMAlimera Sciences Inc : Stonegate Capital Partners Initiates Coverage on Alimera Sciences - Since its founding in 2003, Alimera Sciences, Inc. has focused on researching, developing and commercializing therapeutics for the eye. In 2005, the Company acquired licensing rights to ILUVIEN®, a long-term corticosteroid implant. Subsequently, Alimera ...
04/28/16 06:20 AMAlimera Sciences Inc. (ALIM) is Trading Lower on Unusual Volume for April 25 - Equities.com - Alimera Sciences Inc. (ALIM) is Trading Lower on Unusual Volume for April 25Equities.comAlimera Sciences Inc. (ALIM) experienced unusually high volume on Apr. 25, as the stock lost 9.34% to a closing price of $2.33. The stock saw 528,870 shares trade hands over the course of the day on 1,762 trades. Given that the stock's average daily ...Stonegate Capital Partners Initiates Coverage on Alimera SciencesBaystreet.caall 2 news articles »
04/27/16 08:01 AMStonegate Capital Partners Initiates Coverage on Alimera Sciences - [Accesswire] - DALLAS, TX / ACCESSWIRE / April 27, 2016 / Stonegate Capital Partners initiates research coverage on Alimera Sciences, Inc. (NASDAQ: ALIM). Company Description Since its founding in 2003, Alimera Sciences, ...
04/27/16 07:14 AMNext Weeks Broker Price Targets For Alimera Sciences, Inc. (ALIM) - Share Trading News - Web Breaking NewsNext Weeks Broker Price Targets For Alimera Sciences, Inc. (ALIM)Share Trading News09/29/2014 – Alimera Sciences, Inc. had its “outperform” rating reiterated by analysts at Northland Securities. They now have a USD 10 price target on the stock. Alimera Sciences, Inc. has a 50 day moving average of 1.87 and a 200 day moving average of ...L.P. Bavp Sells 478673 Shares of Alimera Sciences Inc (ALIM) StockWeb Breaking NewsSmall-cap Pharmaceutical Stocks To Watch: Neothetics Inc (NASDAQ:NEOT), Alimera Sciences Inc (NASDAQ:ALIM)Scibility MediaAlimera Sciences to Report First Quarter 2016 Financial Results on May 4, 2016PharmiWeb.com (press release)all 4 news articles »
04/27/16 07:14 AMAlimera Sciences Inc. (ALIM) Drops 9.34% on April 25 - Equities.com - Alimera Sciences Inc. (ALIM) Drops 9.34% on April 25Equities.comAlimera Sciences Inc. (ALIM) was one of the Russell 2000's biggest losers for Monday April 25 as the stock slid 9.34% to $2.33, a loss of $-0.24 per share. Starting at an opening price of $2.53 a share, the stock traded between $2.25 and $2.66 over the ...and more »
04/26/16 09:22 AMAlimera Sciences to Report First Quarter 2016 Financial Results on May 4, 2016 - [at noodls] - April 26, 2016 ATLANTA, April 26, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences (NASDAQ:ALIM), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced ...
04/26/16 06:51 AMAlimera Sciences Incorporated (NASDAQ:ALIM) Shorts Decreased by 2.65% After Short Covering - The stock increased 12.23% or $0.28 on April 22, hitting $2.57. Alimera Sciences Inc (NASDAQ:ALIM) has declined 8.21% since September 17, 2015 and is downtrending. It has underperformed by 13.31% the S&P500. Alimera Sciences, Inc. is a pharmaceutical company.
04/25/16 06:43 AMCould Alimera Sciences Inc Lose Strenght? The Stock Increases A Lot Today - B.O.D.Y Confidential - Could Alimera Sciences Inc Lose Strenght? The Stock Increases A Lot TodayB.O.D.Y ConfidentialThe stock of Alimera Sciences Inc (NASDAQ:ALIM) is a huge mover today! The stock increased 12.23% or $0.28 on April 22, hitting $2.57. About 1.56 million shares traded hands or 561.56% up from the average. Alimera Sciences Inc (NASDAQ:ALIM) has ...
04/25/16 06:43 AMStock Earnings Report: Alimera Sciences (NASDAQ:ALIM) - News Oracle - Stock Earnings Report: Alimera Sciences (NASDAQ:ALIM)News OracleLast Trade: The Company rose 12.23% and finished at $2.57. The daily volume was measured at 1.56 million shares. The 52-week high of the share price is $5.15 and the 52-week low is $1.49. The company has a market cap of $150.89 million. Its latest ...
04/23/16 06:30 AMHighlights of Analyst's Earnings Forecasts: UnitedHealth Group Incorporated (NYSE:UNH), Alimera Sciences, Inc ... - WsNews 4investors - Highlights of Analyst's Earnings Forecasts: UnitedHealth Group Incorporated (NYSE:UNH), Alimera Sciences, Inc ...WsNews 4investorsAlimera Sciences, Inc. (NASDAQ:ALIM) started out trading at $2.35 and hit to day high price of $2.85 while it touched the day low price of $2.35. Shares have gone up +12.23% to close at $2.57. The company shares changing hands with the volume of 1.56 ...and more »
04/23/16 06:30 AMForm 4 ALIMERA SCIENCES INC For: Apr 20 Filed by: Scale Venture Management I, LLC - StreetInsider.com - Form 4 ALIMERA SCIENCES INC For: Apr 20 Filed by: Scale Venture Management I, LLCStreetInsider.comCheck this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 1. Name and Address of Reporting Person *. BAVP, L.P.. (Last), (First), (Middle). 950 TOWER LANE, SUITE 700. (Street). FOSTER CITY, CA ...and more »
04/23/16 06:30 AMAlimera Sciences Inc. (ALIM) Hits New 52-week High During April 21 Session - Equities.com - Alimera Sciences Inc. (ALIM) Hits New 52-week High During April 21 SessionEquities.comAlimera Sciences Inc. (ALIM) hit a new 52-week high yesterday, reaching a peak of $5.15 after opening at $1.99 and closing at $2.29 for a move of 16.24%. Hitting a new 52-week high is a notable milestone for any company, and it can mean a trading ...and more »
03/15/16 03:06 PMALIMERA SCIENCES INC Files SEC form 10-K, Annual Report -
03/08/16 03:08 PMALIMERA SCIENCES INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
03/03/16 12:18 PMEdited Transcript of ALIM earnings conference call or presentation 3-Mar-16 3:00pm GMT -
03/03/16 05:11 AMALIMERA SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition -
About Alimera Sciences

Alimera Sciences logoAlimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ALIM
  • CUSIP:
Key Metrics:
  • Previous Close: $1.49
  • 50 Day Moving Average: $1.61
  • 200 Day Moving Average: $2.03
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $63.13M
  • Current Quarter EPS Consensus Estimate: $-0.69 EPS
Additional Links:
Alimera Sciences (NASDAQ:ALIM) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha